The nurse is assessing a patient for contraindications to drug therapy with acetaminophen.
Which patient should not receive acetaminophen?
A patient with a history of peptic ulcer disease
A patient with a history of liver disease
A patient who is complaining of a mild headache
A patient with a fever of 101°F (38.3°C)
The Correct Answer is B
A. Acetaminophen is generally considered safe for patients with a history of peptic ulcer disease.
It does not irritate the gastrointestinal mucosa like nonsteroidal anti-inflammatory drugs (NSAIDs).
B. Patients with a history of liver disease should not receive acetaminophen or should use it with caution and under close supervision, as acetaminophen is metabolized in the liver. Liver
impairment can lead to decreased metabolism of acetaminophen, potentially resulting in drug accumulation and hepatotoxicity.
C. Acetaminophen is commonly used to relieve mild to moderate headaches. However, the appropriateness of acetaminophen use in this scenario depends on the patient's overall health status and any contraindications specific to the individual.
D. Acetaminophen is often used to reduce fever. A fever of 101°F (38.3°C) alone does not necessarily contraindicate acetaminophen use, but caution should be exercised in patients with liver disease.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is ["0.6"]
Explanation
To find out how many milliliters (mL) of methylnaltrexone should be administered to achieve a dose of 12 mg, we need to set up a proportion based on the available concentration.
Given:
- Methylnaltrexone concentration: 8 mg per 0.4 mL
- Desired dose: 12 mg
We can set up the proportion as follows:
8 /0.4 = 12 / x
Where ( x ) is the unknown amount of methylnaltrexone in milliliters.
To solve for ( x ), we can cross multiply and then divide:
8x = 0.4 12
8x = 4.8
x = 4.8/8
x = 0.6
Therefore, the nurse should administer 0.6 mL of methylnaltrexone.
Correct Answer is A
Explanation
A. Carbidopa prevents the breakdown of levodopa in the periphery, specifically in the gastrointestinal tract and peripheral tissues, allowing more levodopa to reach the brain and be converted to dopamine. This enhances the effectiveness of levodopa therapy in managing the symptoms of Parkinson's disease.
B. Carbidopa is not the biologic precursor of dopamine. It is a peripheral decarboxylase inhibitor that does not cross the blood-brain barrier.
C. Carbidopa does not directly allow for larger doses of levodopa to be given. However, by
inhibiting the peripheral breakdown of levodopa, it enhances the availability of levodopa to the central nervous system, potentially improving therapeutic efficacy.
D. While levodopa-carbidopa combination therapy may have fewer drug-food interactions compared to levodopa alone, the primary reason for combining these medications is to enhance the effectiveness of levodopa by preventing its peripheral breakdown.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.